Home>
US Stocks>
Celldex Therapeutics, Inc.

Celldex Therapeutics, Inc. share price today

(CLDX)

Celldex Therapeutics, Inc. share price is $26.77 & ₹2,265.89 as on 7 Dec 2024, 2.30 'hrs' IST

$26.77

▲

0.71

(2.72%)

Market is closed - opens 8 PM, 09 Dec 2024

View live Celldex Therapeutics, Inc. share price in Dollar and Rupees. Guide to invest in Celldex Therapeutics, Inc. from India. Also see the sentimental analysis on Indian investors investing in Celldex Therapeutics, Inc.. Get details on the Indian mutual funds that are investing in Celldex Therapeutics, Inc.. Get Analyst recommendations and forecasts along with all the Celldex Therapeutics, Inc.'s financials.

Celldex Therapeutics, Inc. share price movements

$26.09
$27.10
$26.77
2.54%
Downside
Day's Volatility :3.73%
Upside
1.22%
$22.93
$53.18
$26.77
14.35%
Downside
52 Weeks Volatility :56.88%
Upside
49.66%

Celldex Therapeutics, Inc. Returns

Period	Celldex Therapeutics, Inc.	Sector (Health Care)	Index (Russel 2000)
3 Months	-38.36%	-5.7%	0.0%
6 Months	-24.77%	-0.8%	0.0%
1 Year	-17.09%	9.9%	0.0%
3 Years	-34.41%	10.7%	-19.7%

Celldex Therapeutics, Inc. Key Statistics

in dollars & INR

Previous Close	$26.06
Open	$26.34
Today's High	$27.1
Today's Low	$26.09
Market Capitalization	$1.8B
Today's Volume	$569.3K
52 Week High	$53.18
52 Week Low	$22.9291
Revenue TTM	$10.0M
EBITDA	$-171.1M
Earnings Per Share (EPS)	$-2.53
Profit Margin	0.0%
Quarterly Earnings Growth YOY	0.0%
Return On Equity TTM	-29.84%

How to invest in Celldex Therapeutics, Inc. from India?

It is very easy for Indian residents to invest directly in Celldex Therapeutics, Inc. from India. Indian investors can open a free US stocks account on the INDmoney app. You can find live prices of the Celldex Therapeutics, Inc. stock in both rupees (INR) and dollars (USD). Search for Celldex Therapeutics, Inc. or CLDX on INDmoney app and click on Buy or SIP. You can invest by choosing quantities of shares of Celldex Therapeutics, Inc. or Rupee/ Dollar value or set up a fixed SIP amount to be invested every month or week.

For example: You can easily buy Rs.100 worth of Celldex Therapeutics, Inc. shares which would translate to 0.032 fractional shares of Celldex Therapeutics, Inc. as of today. Learn more about fractional investing here.

Indians via INDmoney can now also, easily transfer and add their money to the US stocks account via INDmoney App. Click here for step by step process for the same

Indian investors sentiment towards Celldex Therapeutics, Inc.

Period: Sep 7, 2024 to Dec 6, 2024. Change in 30 Days versus previous period

Search volume for Celldex Therapeutics, Inc. on INDmoney from India has grown in the last 30 days as on Dec 7, 2024. 9% more investors are searching Celldex Therapeutics, Inc. in the last 30 days versus the previous period.

Global Institutional Holdings in Celldex Therapeutics, Inc.

Wellington Management Company LLP
13.93%
FMR Inc
9.08%
BlackRock Inc
7.07%
Vanguard Group Inc
5.83%
Kynam Capital Management, LP
5.21%
Eventide Asset Management, LLC
5.02%

Analyst Recommendation on Celldex Therapeutics, Inc.

Buy

85%Buy

14%Hold

0%Sell

Based on 14 Wall street analysts offering stock ratings for Celldex Therapeutics, Inc.(by analysts ranked 0 to 5 stars)

Based on 14 analyst

Current
1M Ago
3M Ago

Buy

Hold

Sell

Analyst Forecast on Celldex Therapeutics, Inc.

What analysts predicted

Upside of 150.65%

Current:

$26.77

Target:

$67.10

Insights on Celldex Therapeutics, Inc.

Increasing Revenue
Revenue is up for the last 3 quarters, 156.0K → 3.19M (in $), with an average increase of 57.7% per quarter
Decreasing Net Profit
Netprofit is down for the last 3 quarters, -32.80M → -42.12M (in $), with an average decrease of 13.4% per quarter
Vs ALNY
In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 43.9% return, outperforming this stock by 61.4%
Vs VRTX
In the last 3 years, Vertex Pharmaceuticals Incorporated has given 42.3% return, outperforming this stock by 70.7%

Celldex Therapeutics, Inc. Financials in INR & Dollars

	FY18	Y/Y Change
Revenue	$9.5M	↓ 25.15%
Net Income	$-151.2M	↑ 62.51%
Net Profit Margin	-1.6K%	↓ 855.01%

	FY19	Y/Y Change
Revenue	$3.6M	↓ 62.54%
Net Income	$-50.4M	↓ 66.68%
Net Profit Margin	-1.4K%	↑ 175.27%

	FY20	Y/Y Change
Revenue	$7.4M	↑ 107.61%
Net Income	$-59.8M	↑ 18.68%
Net Profit Margin	-805.88%	↑ 603.92%

	FY21	Y/Y Change
Revenue	$4.7M	↓ 37.3%
Net Income	$-70.5M	↑ 17.95%
Net Profit Margin	-1.5K%	↓ 710.16%

	FY22	Y/Y Change
Revenue	$2.4M	↓ 49.32%
Net Income	$-122.8M	↑ 74.13%
Net Profit Margin	-5.2K%	↓ 3693.25%

	FY23	Y/Y Change
Revenue	$6.9M	↑ 192.02%
Net Income	$-141.4M	↑ 15.19%
Net Profit Margin	-2.1K%	↑ 3154.53%

	Q2 FY23	Q/Q Change
Revenue	$268.0K	↓ 72.29%
Net Income	$-30.5M	↑ 36.08%
Net Profit Margin	-11.4K%	↓ 9063.35%

	Q3 FY23	Q/Q Change
Revenue	$1.5M	↑ 466.04%
Net Income	$-38.3M	↑ 25.43%
Net Profit Margin	-2.5K%	↑ 8859.26%

	Q4 FY23	Q/Q Change
Revenue	$4.1M	↑ 172.31%
Net Income	$-43.3M	↑ 13.19%
Net Profit Margin	-1.0K%	↑ 1473.76%

	Q1 FY24	Q/Q Change
Revenue	$156.0K	↓ 96.22%
Net Income	$-32.8M	↓ 24.24%
Net Profit Margin	-21.0K%	↓ 19982.45%

	Q2 FY24	Q/Q Change
Revenue	$2.5M	↑ 1501.28%
Net Income	$-35.8M	↑ 9.25%
Net Profit Margin	-1.4K%	↑ 19595.94%

	Q3 FY24	Q/Q Change
Revenue	$3.2M	↑ 27.74%
Net Income	$-42.1M	↑ 17.52%
Net Profit Margin	-1.3K%	↑ 114.84%

	FY18	Y/Y Change
Total Assets	$155.8M	↓ 50.63%
Total Liabilities	$31.7M	↓ 59.94%

	FY19	Y/Y Change
Total Assets	$122.9M	↓ 21.1%
Total Liabilities	$28.9M	↓ 8.95%

	FY20	Y/Y Change
Total Assets	$235.8M	↑ 91.84%
Total Liabilities	$26.5M	↓ 8.39%

	FY21	Y/Y Change
Total Assets	$444.7M	↑ 88.54%
Total Liabilities	$25.2M	↓ 4.92%

	FY22	Y/Y Change
Total Assets	$352.7M	↓ 20.67%
Total Liabilities	$26.5M	↑ 5.37%

	FY23	Y/Y Change
Total Assets	$465.6M	↑ 32.0%
Total Liabilities	$36.5M	↑ 37.41%

	Q2 FY23	Q/Q Change
Total Assets	$299.3M	↓ 7.77%
Total Liabilities	$21.8M	↓ 0.02%

	Q3 FY23	Q/Q Change
Total Assets	$280.3M	↓ 6.37%
Total Liabilities	$33.5M	↑ 54.03%

	Q4 FY23	Q/Q Change
Total Assets	$465.6M	↑ 66.14%
Total Liabilities	$36.5M	↑ 8.7%

	Q1 FY24	Q/Q Change
Total Assets	$868.8M	↑ 86.6%
Total Liabilities	$30.2M	↓ 17.07%

	Q2 FY24	Q/Q Change
Total Assets	$845.6M	↓ 2.68%
Total Liabilities	$31.9M	↑ 5.6%

	Q3 FY24	Q/Q Change
Total Assets	$823.2M	↓ 2.65%
Total Liabilities	$37.3M	↑ 16.75%

	FY18	Y/Y Change
Operating Cash Flow	$-75.2M	↓ 24.71%
Investing Cash Flow	$29.8M	↓ 35.84%
Financing Cash Flow	$29.4M	↓ 42.6%

	FY19	Y/Y Change
Operating Cash Flow	$-46.4M	↓ 38.31%
Investing Cash Flow	$17.1M	↓ 42.72%
Financing Cash Flow	$16.3M	↓ 44.78%

	FY20	Y/Y Change
Operating Cash Flow	$-40.4M	↓ 12.95%
Investing Cash Flow	$-98.2M	↓ 675.05%
Financing Cash Flow	$171.2M	↑ 953.24%

	FY21	Y/Y Change
Operating Cash Flow	$-60.9M	↑ 50.75%
Investing Cash Flow	$-216.2M	↑ 120.08%
Financing Cash Flow	$272.4M	↑ 59.07%

	FY22	Y/Y Change
Operating Cash Flow	$-103.7M	↑ 70.31%
Investing Cash Flow	$89.9M	↓ 141.61%
Financing Cash Flow	$4.1M	↓ 98.5%

	Q2 FY23	Q/Q Change
Operating Cash Flow	$-27.2M	↓ 4.81%
Investing Cash Flow	$1.2M	↓ 97.79%
Financing Cash Flow	$133.0K	↓ 80.84%

Celldex Therapeutics, Inc. Technicals Summary

Sell

Neutral

Buy

Celldex Therapeutics, Inc. is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

Celldex Therapeutics, Inc. Vs Peers

Company Name	1 Month	6 Month	1 Year	3 Years	5 Years
Celldex Therapeutics, Inc.	-5.68%	-24.77%	-17.09%	-34.41%	1033.04%
Regeneron Pharmaceuticals, Inc.	-5.97%	-23.34%	-8.6%	17.41%	110.02%
Biontech Se	11.44%	21.29%	14.9%	-59.29%	309.79%
Alnylam Pharmaceuticals, Inc.	-7.77%	64.08%	48.09%	42.33%	108.61%
Vertex Pharmaceuticals Incorporated	-6.83%	-4.83%	31.35%	122.6%	109.65%

Company Name	P/E Ratio	P/B Ratio	PEG Ratio	EPS	ROE	ROA	Div Yield	BVPS
Celldex Therapeutics, Inc.	NA	NA	0.0	-2.4	-0.3	-0.2	NA	11.85
Regeneron Pharmaceuticals, Inc.	18.56	18.56	1.12	44.92	0.17	0.07	NA	272.04
Biontech Se	160.8	NA	0.04	-3.06	-0.02	-0.01	NA	79.73
Alnylam Pharmaceuticals, Inc.	NA	NA	-0.49	-0.19	-15.01	-0.03	NA	0.25
Vertex Pharmaceuticals Incorporated	32.84	NA	1.21	0.54	-0.03	0.12	NA	60.65

Company Name	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin
Celldex Therapeutics, Inc.	Buy	$1.8B	1033.04%	NA	0.0%
Regeneron Pharmaceuticals, Inc.	Buy	$82.9B	110.02%	18.56	33.61%
Biontech Se	Buy	$28.5B	309.79%	160.8	-15.36%
Alnylam Pharmaceuticals, Inc.	Buy	$32.7B	108.61%	NA	-15.86%
Vertex Pharmaceuticals Incorporated	Buy	$118.4B	109.65%	32.84	-4.51%

Celldex Therapeutics, Inc. Dividend announcements

Celldex Therapeutics, Inc. Earnings
Celldex Therapeutics, Inc.’s price-to-earnings ratio stands at None
Read More

About Celldex Therapeutics, Inc.

celldex is developing targeted therapeutics to address devastating diseases for which available treatments are inadequate. our pipeline is built from a proprietary portfolio of antibodies and immunomodulators used alone and in strategic combinations to create novel, disease-specific therapies that induce, enhance or suppress the body's immune response. celldex therapeutics (nasdaq: cldx) was founded based on a fundamental scientific belief that harnessing the power of the immune system would break significant barriers in drug development for a host of devastating diseases. the company's pipeline is comprised of therapeutic antibodies, antibody drug conjugates, immune system modulators and vaccines that we believe have a higher probability of success because they are targeted to specific patient populations with high unmet medical need whose diseases express specific markers, including many underserved or completely un-served orphan indications. this has created a leading pipeline in im

Organization	Celldex Therapeutics, Inc.
Employees	160
CEO	Mr. Anthony S. Marucci M.B.A.
Industry	Health Technology

Management People of Celldex Therapeutics, Inc.

Name	Title
Mr. Anthony S. Marucci M.B.A.	Founder, President, CEO & Director
Dr. Tibor Keler Ph.D.	Founder, Chief Scientific Officer & Executive VP
Mr. Sam Martin CPA	Senior VP, CFO, Secretary & Treasurer
Dr. Margo Heath-Chiozzi M.D.	Senior Vice President of Regulatory Affairs
Dr. Diane C. Young M.D.	Senior VP & Chief Medical Officer
Prof. Joseph P. Schlessinger Ph.D.	Co-Founder & Member of Scientific Advisory Board
Ms. Sarah Cavanaugh	Senior Vice President of Corporate Affairs & Administration
Mr. Freddy A. Jimenez Esq.	Senior VP & General Counsel
Dr. Ronald A. Pepin	Chief Business Officer & Senior VP
Ms. Elizabeth Crowley	Chief Product Development Officer & Senior VP

Important FAQs about investing in Celldex Therapeutics, Inc. from India :

What is Celldex Therapeutics, Inc. share price today?

Celldex Therapeutics, Inc. (CLDX) share price today is $26.77.

Can Indians buy Celldex Therapeutics, Inc. shares?

Yes, Indians can invest in the Celldex Therapeutics, Inc. (CLDX) from India.

With INDmoney, you can buy Celldex Therapeutics, Inc. at 0 brokerage. The step-by-step process is as follows:

Open your zero cost US Stocks account and zero balance IND linked savings a/c (this can be done in less than 3 minutes)
Transfer funds to your US Stocks account using your IND linked savings a/c (It takes 24 hours excluding Saturday and Sunday). With INDmoney, you get the best INR USD exchange rates.
Once funds are transferred successfully, you can buy Celldex Therapeutics, Inc. at zero transaction cost.

How can I buy Celldex Therapeutics, Inc. shares from India?

It is very easy to buy Celldex Therapeutics, Inc. from India. With INDmoney, you can open a US stocks account in less than 3 minutes. Transfer funds in 24 hours and buy stocks very easily - that too at 0 brokerage. All this is done at 0 account opening & management fee, 0 brokerages, and at the same time you get the best rupee-US dollar exchange rate.

Can Fractional shares of Celldex Therapeutics, Inc. be purchased?

Yes, you can buy fractional shares of Celldex Therapeutics, Inc. with INDmoney app.

What are the documents required to start investing in Celldex Therapeutics, Inc. stocks?

To start investing in Celldex Therapeutics, Inc., You will need the following documents:

Proof of Identification (PAN, Aadhaar etc)
Proof of address (Aadhaar, Voter ID etc)

These documents are required as per RBI's guidelines to create your IND linked savings a/c so that you can execute for global fund transfer. The entire process is paperless and can be completed seamlessly.